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Background/Aims: Among borderline resectable pancreatic 
cancer (BRPC), group B BRPC patients have findings that are 
suggestive but not diagnostic of metastasis. In this study, we 
attempted to validate whether group B could truly be catego-
rized as a borderline resectable group. Methods: We placed 
the BRPC patients into group A or group B. The survival out-
comes were compared between the groups. Results: A total 
of 53 patients with pancreatic adenocarcinoma was clas-
sified as either group A or B borderline resectable. In group 
A, 23 (60.5%) of 38 patients underwent pancreatectomy 
after concurrent chemoradiotherapy or chemotherapy, but in 
group B, only five (33.3%) of 15 patients underwent pancre-
atectomy, mainly because of the progression of suspected 
distant metastasis. There was a significant difference in 
overall survival (OS) between group A and B patients (median 
OS, 21.2 months vs 10.2 months, respectively; p=0.007). Of 
the patients who underwent pancreatectomy, group B had 
a higher recurrence rate compared to group A (recurrence 
rate: 11 of 23 patients [47.8%] vs five of five patients [100%], 
respectively; p=0.033). Conclusions: This report is the first 
to validate the definition of BPRC. Group B had much worse 
outcomes, and whether group B BRPC can be categorized 
as BRPC together with group A is questionable. (Gut Liver 
2014;8:557-562)
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INTRODUCTION
Pancreatic cancer is usually diagnosed at an advanced stage, 
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such that two-thirds of patients have locally advanced or meta-
static disease at the time of diagnosis. For patients with Ameri-
can Joint Committee on Cancer (AJCC) stage I and II pancreatic 
adenocarcinoma who undergo a successful pancreatectomy, 
the 5-year survival rate is approximately 15% to 20%;1 how-
ever, surgery is not an option for patients who are diagnosed 
with locally advanced (AJCC stage III) disease. Indeed, for these 
patients, the median survival is usually less than 12 months de-
spite the use of chemotherapy and/or chemoradiation therapy.2 
Recently, the concept of borderline resectable pancreatic cancer 
(BRPC) was introduced. This type of pancreatic cancer is po-
sitioned on the spectrum between resectable and unresectable 
pancreatic cancer. It is potentially resectable and thus curable, 
but tumor free margins are hard to achieve and the surgical 
outcome is not as good as that for resectable pancreatic cancer.3
In 2006, Varadhachary et al.1 from MD Anderson Cancer Cen-
ter proposed an objectively defined BRPC. A computed tomog-
raphy (CT)-based classification, which distinguished borderline 
resectable from both resectable and locally advanced pancreatic 
cancer, was reported.1 In 2008, Katz et al.2 reported 160 patients 
with borderline resectable disease treated at MD Anderson Can-
cer Center and introduced three types of borderline resectable 
disease, now often referred to as Katz type A, B, and C. All three 
groups of BRPC were categorized as borderline resectable be-
cause they had conflicting potential for either complete remis-
sion or disease progression such as distant metastasis. Recently, 
BRPC gains a lot of attention because there have been several 
reports that preoperative multimodality treatment can improve 
resectability rate and surgical treatment outcome. Specially in 
terms of treatment, concurrent chemoradiotherapy (CCRT) or 
chemotherapy can be the preoperative treatment options for 
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BRPC. Preoperative therapy may downstage the borderline re-
sectable disease and make complete resection possible and select 
patients suitable for surgery, which could translate to a survival 
benefit after resection.4,5 Especially for group A, several studies 
reported that survival outcome could be improved with preop-
erative treatment.6-9 For example, Kalser and Ellenberg6 reported 
that BRPC had better survival outcome with preoperative CCRT 
compared to the patients without preoperative treatment (median 
survival, 20.0 months vs 10.99 months; p<0.05).
Still, an understanding of these groups of patients has not 
been established due to the inconsistencies and imprecision in 
both the definitions and standard treatment algorithms. Above 
mentioned approach is tested mostly in type A BRPC and, even 
though type B is categorized together with group A, there is not 
enough data to prove that type B could be treated like type A 
BRPC. Thus, in this study, we tried to validate whether group 
B BRPC could be truly categorized in the borderline resectable 
group.
MATERIALS AND METHODS
1. Study population
All patients who were evaluated for group A or B BRPC and 
received CCRT or chemotherapy between November 2005 and 
April 2012 were enrolled in this study. The patients in this study 
were divided into group A or B according to the MD Anderson 
criteria. We defined group B patients who had suggestive meta-
static lesions. Suggestive metastasis includes suspicious distant 
lymph node, liver metastasis, or carcinomatosis. Suspicious dis-
tant lymph node was defined as 8 mm sized or more for short 
axis diameter at distant lymph node area such as paraaortic 
area. But, all of lymph node was not definite for metastasis 
depend on radiologists’ decision. Suspicious liver metastasis or 
carcinomatosis was decided based on location, size, and char-
acteristics of the lesions. The decision was made by radiologist. 
Even if careful and experienced radiologic review was done, 
some metastatic lesion could not be concluded whether the le-
sion is malignant or not. For such cases, we defined these pa-
tients as group B and we tried to conclude malignancy potential 
by follow-up of imaging study after chemotherapy or CCRT. 
Group C BRPC and patients included in both group A and B 
were not included in our study. Patients with mucinous cystic 
neoplasm, invasive intraductal papillary mucinous neoplasm, 
and other nonpancreatic adenocarcinomas of the periampul-
lary region were also excluded. Baseline characteristics of all 
patients were based on a basic blood test (complete blood count 
and blood chemistries) and contrast-enhanced CT, magnetic 
resonance imaging (MRI) of the abdomen, and endoscopic ul-
trasound. Serum CA19-9 levels were recorded at the time of 
diagnosis. The rate of operation, recurrence rate, disease-free 
survival (DFS), progression-free survival (PFS), and overall sur-
vival (OS) were compared between group A and group B BRPC.
2. Treatment modality and follow-up
All patients received initial treatment with CCRT or chemo-
therapy. In case of CCRT, the total radiation therapy dose was 
approximately 5,040 cGy. Representative concomitant chemo-
therapy consisted of 5-fluorouracil, gemcitabine, or capecitabine 
at radiosensitizing doses. In case of chemotherapy, gemcitabine-
based chemotherapy was performed. For response evaluation of 
CCRT or chemotherapy, abdominal CT or MRI was done. Based 
on result of follow-up imaging study, a Whipple’s operation, 
pancreaticoduodenectomy, or distal pancreatectomy was per-
formed if the cancer lesion was judged operable. After the oper-
ation, patients were evaluated every 1 to 2 months by physical 
examination, complete blood count, blood chemistries, tumor 
marker (CA19-9) level, and abdominal CT or MRI. All patients 
who underwent surgery were recommended to receive adjuvant 
chemotherapy. Patients who could not undergo surgery received 
gemcitabine-based systemic chemotherapy.
3. Statistical analysis
The primary end points were OS, DFS, and PFS. OS was cal-
culated from the date of diagnosis until death from any cause or 
the patient’s last visit to the hospital. DFS was calculated from 
the date of operation until the date of recurrence or the day of 
the last radiological evaluation such as CT or MRI. PFS was cal-
culated from the date of diagnosis until the date of progression 
or the day of the last radiological evaluation.
The OS, DFS, PFS, and 3-year survival rate were calculated 
using the Kaplan-Meier method. Differences between OS curves 
were assessed by the log rank test. All analyses were performed 
with the SPSS statistical program version 18.0 (IBM Co., Ar-
monk, NY, USA). A p<0.05 was considered statistically signifi-
cant.
RESULTS
1. Baseline characteristics and clinical variables
Fifty-three of 703 patients (7.5%) with pancreatic adenocar-
cinoma were classified as borderline resectable, with 38 type 
A (71.7%) and 15 type B (28.3%). The median age of patients 
was 62 years (range, 38.0 to 83.0 years), and the sex ratio 
(male:female) was 32:21. Most of the BRPC cases in our study 
were located at the head of the pancreas (45, 84.9%). The medi-
an pretreatment CA19-9 level was 295 U/mL (range, 0.1 to 5,320 
U/mL). The baseline characteristics of group A and B BRPC are 
described in Table 1. Between group A and B BRPC, there were 
no significant differences for the median patient age, gender, 
and pretreatment CA19-9 level.
2. Treatment
All 53 patients completed scheduled CCRT or chemotherapy. 
Mean duration of induction therapy was about 5 weeks. After 
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that, 33 of 53 patients (62.3%) had a favorable response. Six 
patients (11.3%) had a partial response, 27 patients (50.9%) had 
stable disease, and 20 patients (37.7%) had disease progression. 
In a subgroup analysis, group B had fewer favorable responses 
compared to group A. Eleven out of 38 patients (28.9%) in 
group A and nine out of 15 patients (60%) in group B had dis-
ease progression (Table 2). Among nine patients of group B who 
had disease progression after induction therapy, seven patients 
(77.8%) had progression of suspicious metastatic lesions. At the 
time of restaging evaluation, 28 of 53 patients (52.8%) were 
determined to be eligible for operation. In group A, 23 of 38 pa-
tients (60.5%) underwent pancreatectomy, but in group B, only 
five of 15 patients (33.3%) underwent pancreatectomy. Group B 
BRPC (33.3%) had the tendency to have a lower rate of opera-
tion compared to group A BRPC (60.5%) (p=0.074). Preoperative 
and operative data for 28 patients who had a pancreatectomy 
are described in Table 3. Venous resection was performed in 13 
out of 28 patients (46.4%) and none of these patients required 
short-segment resection of the common hepatic artery. Through 
surgical pathologic evaluation, 18 of 23 patients (78.3%) in 
group A and three of five patients (60.0%) in group B were con-
firmed to have R0 resection (p=0.418). Regarding the pathologi-
cal nodal stage, one of 23 patients (3.6%) in group A and one of 
five patients (20.0%) in group B had confirmed to have lymph 
node metastasis (p=0.218).
3. Survival outcome
The median follow-up time was 13.6 months. The 3-year OS 
rate of patients with BRPC was 31%. At the time of last follow-
up, 17 of 38 (44.7%) and 11 of 15 patients (73.3%) in group A 
and B BRPC died, respectively (p=0.060). The OS of group A 
was longer than that for group B (median OS, 21.2 months vs 
10.2 months; p=0.007) (Fig. 1). In addition, the PFS of group A 
was longer than that for group B (median PFS, 12.2 months vs 
Table 1. Baseline Characteristics of Group A and B Borderline Resect-
able Pancreatic Cancer Patients
Characteristic All patients
Borderline resectable type
p-value
Group A Group B
Total patients, no. 53 38 15
Age, yr 62 (38–83) 59 (38–83) 64 (44–80) 0.974
Gender 0.972
    Male 32 (60.4) 23 (60.5) 9 (60.0)
    Female 21 (39.6) 15 (39.5) 6 (40.0)
Tumor location in 
  pancreas
0.001
    Head/Uncinate 45 (84.9) 36 (94.7) 9 (60.0)
    Body/Tail 8 (15.1) 2 (5.3) 6 (40.0)
Pretreatment CA19-9, 
  U/mL
    All 295
(0.1–5,320)
272
(0.1–5,320)
417
(0.1–1,810)
0.371
    Underwent 
      pancreatectomy
272
(0.1–3,540)
304
(0.1–3,540)
57
(0.1–452)
0.226
    Did not undergo 
      pancreatectomy
417
(0.1–5,320)
148
(0.1–5,320)
522
(0.1–1,810)
0.628
Pancreatectomy 
  performed
0.074
    Yes 28 (52.8) 23 (60.5) 5 (33.3)
    No 25 (47.2) 15 (39.5) 10 (66.7)
Data are presented as median (range) or number (%).
Table 2. A Comparison of the Survival Outcomes between Groups A 
and B Borderline Resectable Pancreatic Cancer for All 53 Patients
Group A Group B Total p-value
Total, no. 38 15 53
Induction therapy 
Response rate
0.036
    Progression 11 (28.9) 9 (60) 20 (37.7)
    Nonprogression 27 (71.1) 6 (40) 33 (62.3)
Resected 23 (60.5) 5 (33.3) 28 (52.8) 0.074
Overall survival, mo 21.2 10.2 18.5 0.007
Progression-free survival,
  mo
12.2 5.2 10.1 0.001
3-Year survival rate, % 40 13 31
Data are presented as number (%).
Table 3. The Preoperative and Operative Data for 28 Patients Who 
Underwent Pancreatectomy
Characteristic All patients Group A Group B p-value
Total patients, no. 28 23 5
Restaging (postoperative)
  CA 19-9, U/mL
66.1
(0.1–1,230)
70.2
(0.1–1,230)
34.0 
(0.1–845)
0.899
Surgical procedure 0.448
    PPPD 21 (75.0) 18 (78.3) 3 (60.0)
    Whipple's operation 5 (17.9) 4 (17.4) 1 (20.0)
    Distal pancreatectomy 2 (7.1) 1 (4.3) 1 (20.0)
    Etc. 0 0 0
Vascular resection 0.502
    Hepatic artery 0 0 0
    SMV/PV 13 (46.4) 10 (43.5) 3 (60.0)
Margin status 0.393
    R0 21 (75.0) 18 (78.3) 3 (60.0)
    R1 7 (25.0) 5 (21.7) 2 (40.0)
Adjuvant chemotherapy 18 (64.3) 14 (60.9) 4 (80.0) 0.418
Data are presented as median (range) or number (%).
PPPD, pylorus preserving pancreatoduodenectomy; SMV/PV, superior 
mesenteric vein/portal vein.
560  Gut and Liver, Vol. 8, No. 5, September 2014
5.2 months; p=0.001) (Table 2). Of the patients who underwent 
pancreatectomy, group B patients (five of five patients, 100%) 
had a significantly higher recurrence rate compared to group 
A patients (11 of 23 patients, 47.8%; odds ratio, 1.455; 95% 
confidence interval, 1.045 to 2.024; p=0.033). When we com-
pared the characteristics of recurrence type among the patients 
who had surgery, among group A patients who had recurrence 
after surgery, four of 11 patients (36.4%) had metastatic recur-
rence and seven of 11 patients (63.6%) had local recurrence. In 
five patients of group B who had recurrence after surgery, four 
of five patients (80%) had metastatic recurrence and only one 
of five patients (20%) had local recurrence. Due to insufficient 
patients’ number who had surgery in group B, despite lower R0 
resection rate in group B, local recurrence rate in group B was 
lower than group A. The portion of metastatic recurrence was 
higher in group B patients compared to group A patients. Group 
B also showed a shorter DFS compared to group A (median 
DFS, 29.0 months vs 8.3 months; p=0.054) (Table 4).
4. Subgroup analysis of group B borderline resectable pan-
creatic cancer
Among group B patients, 10 of 15 patients were suspicious of 
distant lymph node metastasis such as paraaortic lymph node 
metastasis, three of 15 patients were suspicious of carcinoma-
tosis, and two of 15 patients were suspicious of liver metastasis. 
After CCRT or surgery, five of 10 patients were confirmed dis-
tant lymph node metastasis, two of three patients were con-
firmed carcinomatosis, and two of two patients were confirmed 
liver metastasis. Among the six patients who still had inconclu-
sive lesion even after chemotherapy or CCRT, five patients had 
favorable response for first induction therapy. Compared to the 
group B patients who were concluded to have metastatic lesion 
after induction therapy, these six patients could be expected 
better prognosis.
DISCUSSION
Group A BRPC is defined by the following anatomic char-
acteristics: tumor abutment (≤180° of the circumference of the 
vessel) of the superior mesenteric artery or celiac axis; tumor 
abutment or encasement (>180° of the circumference of the ves-
sel) of a short segment of the hepatic artery; or short-segment 
occlusion of the superior mesenteric vein (SMV), portal vein 
(PV), or SMV-PV confluence. Group B borderline resectable 
disease raises a concern for possible extrapancreatic metastatic 
disease. This subgroup of borderline resectable patients includes 
those with CT findings suspicious for, but not diagnostic of, 
metastatic disease. Based on the decision regarding suspicious 
metastatic lesions, group B BRPC can be categorized as both 
resectable and unresectable. Thus, it has been classified as a 
borderline resectable group. Patients of group C have borderline 
resectable disease due to a marginal performance status. Group 
C also encompasses patients with a better performance status 
and a severe pre-existing medical comorbidity.10 Due to equivo-
cal anatomical characteristics of group A, the potential for dis-
tant metastasis in group B, and the equivocal general condition 
for group C, all three types of BRPC have been categorized as 
borderline resectable. But, whether all three types of BRPC had 
similar potential for resectabiliy is questionable and these three 
groups had distinctly different characteristics. Especially for 
group B BRPC, its definition is ambiguous.
Until now, in contrast to group A BRPC, it had not been 
determined whether group B BRPC could truly be considered 
BRPC. Potential resectability is a quality consistent with BRPC, 
but the chance of systemic spread is not. Whether group B BRPC 
can truly be categorized as borderline resectable is an important 
point when deciding treatment options. If it can be considered a 
localized disease just like group A BRPC, surgery possibly with 
vascular resection after local induction therapy such as CCRT is 
a logical approach; however, if it is considered a systemic dis-
ease, then systemic therapy is more suitable, and the chance of 
resection will not be high. Until now, it seems that both group 
A and B have been regarded just as BRPC, and the treatment 
approach has not been very different for the two categories.11 In 
this study, we showed that unfortunately, group B BRPC had a 
worse treatment outcome than group A. The rate of operation 
was low, and the recurrence rate was high. All patients in group 
Fig. 1. Kaplan-Meier overall survival curves for group A and B bor-
derline resectable pancreatic cancer (p=0.007).
Table 4. A Comparison of the Prognoses between Groups A and B 
Borderline Resectable Pancreatic Cancer for 28 Patients Who Under-
went Pancreatectomy
Group A Group B Total p-value
Total, no. 23 5 28
Overall survival, mo 38.3 18.1 35.4 0.088
Recurred, no. (%) 11 (47.8) 5 (100.0) 16 (57.1) 0.033
Disease-free survival, mo 29 8.3 24 0.054
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B who underwent surgery had recurrence. Considering resection 
rate was low and recurrence rate was high, it was questionable 
that group B could be a candidate for surgery and classified as 
BRPC. Among group B patients in our study, some of them had 
CCRT as local treatment and the other had chemotherapy as 
systemic treatment. Heterogeneity of treatment option could be 
the reason for poor prognosis in group B. If we considered only 
systemic treatment alone, we could expect better treatment out-
come. Our result suggested that treatment approach for group B 
BRPC had to be changed from considering resection to systemic 
approach.
In terms of treatment, preoperative CCRT or chemotherapy 
have several advantages, including the potential for down-stag-
ing advanced pancreatic cancer, the avoidance of unnecessary 
exploratory laparotomy for patients who have rapidly progres-
sive disease,12,13 and the expectation for both local and systemic 
treatment.14,15 In the case of group B BRPC, there are not enough 
studies about treatment algorithms. The biggest concern in 
treating group B BRPC is preexisting micrometastases.13 Asiyan-
bola et al.16 reported a high incidence and clinical significance 
of pre-existing micrometastases in patients with radiographi-
cally localized pancreatic cancer. The high rate of recurrence 
among patients with resected cancers with or without postop-
erative therapy suggests that disseminated cancer cells were 
undetected and incompletely treated.17,18 Our study showed that 
group B BRPC had a poor response rate for CCRT or chemo-
therapy, and preoperative treatment could not raise resectability 
rate and lower recurrence rate. In addition, resection in group B 
BRPC should be reserved for carefully selected patients whose 
cancers are confirmed to not be systemic. Pancreatic cancer not 
progressing after chemotherapy or presence of no distant me-
tastasis was not adequate criteria for surgery in group B unlike 
group A. Having Future clinical trials of preoperative induction 
therapy for BRPC should include group A and group B BRPC 
separately.
There were some limitations of our study. First, induction 
treatment was not uniform and the number of patients was too 
small. Second, we could not show long-term follow-up results 
due to poor survival outcomes. Third, patients’ number is too 
small for accurate validation because we excluded the patients 
who had both characteristics of group A and B BRPC. But, ex-
cluding the patients who had both characteristics of group A 
and B BRPC is inevitable for accurate analysis. Clearly, further 
studies are necessary to establish stage-specific treatment algo-
rithms for this clinically diverse group of patients. Further pro-
spective, long-term studies will be needed.
This is the first report for the validation of group B BRPC. 
Group B BRPC had lower resectability, poorer survival out-
comes, and a higher recurrence rate compared to group A BRPC. 
Group A and B BRPC cannot be categorized together as BRPC 
since group B has very low chance of surgical resection and 
worse prognosis. Group B BRPC is more like borderline systemic 
disease rather than borderline resectable disease.
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